Skip to Main Content

Paper Details

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
Nat Genet
384
2015
BRAF, BRAF V600E, BRAF gene, BRAF gene mutation, BRAF-, BRAF-mutant tumor, BRAF-mutant tumor cells, Hippo, MEK, RAF, RAS, RAS gene, RAS-mutant tumors, V600E, YAP, YAP1, cancer, patient, patients, tumors
Author NameAffiliation
Luping LinUniversity of California, USA. [2] Helen Diller Family Comprehensive Cancer Center san francisco
Elton ChanUniversity of California, USA. [2] Helen Diller Family Comprehensive Cancer Center san francisco
Victor OlivasUniversity of California, USA. [2] Helen Diller Family Comprehensive Cancer Center san francisco
Evangelos PazarentzosUniversity of California, USA. [2] Helen Diller Family Comprehensive Cancer Center san francisco
Saurabh AsthanaUniversity of California, USA. [2] Helen Diller Family Comprehensive Cancer Center san francisco
Saurabh AsthanaUniversity of California, USA. [2] Helen Diller Family Comprehensive Cancer Center san francisco
Dana S NeelUniversity of California, USA. [2] Helen Diller Family Comprehensive Cancer Center san francisco
Jenny Jiacheng YanUniversity of California, USA. [2] Helen Diller Family Comprehensive Cancer Center san francisco
Jose Miguel SanchezHospital Universitario de La Princesa
Charles M RudinMemorial Sloan Kettering Cancer Center
Eric A CollissonUniversity of California, USA. [2] Helen Diller Family Comprehensive Cancer Center san francisco
Jennifer A WargoMD Anderson Cancer Center
Trever G BivonaUniversity of California, USA. [2] Helen Diller Family Comprehensive Cancer Center san francisco
  • 1 - 13

Datasets